CoChat
Sign Up
Cited by 180Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Open access
Trauner, Michael, Nevens, Frederik, Shiffman, Mitchell L, Drenth, Joost P H, Bowlus, Christopher L, Vargas, Victor, Andreone, Pietro, Hirschfield, Gideon M, Pencek, Richard, Malecha, Elizabeth Smoot, MacConell, Leigh, Shapiro, David·2019·The Lancet Gastroenterology & Hepatology
DOI 10.1016/s2468-1253(19)30094-9
Open this paper in CoChat — free account

Abstract

BACKGROUND The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. METHODS In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). FINDINGS 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change -105·2 U/L [SD 87·6]), 24 months (-101·0 U/L [98·5]), 36 months (-108·6 U/L [95·7]), and 48 months (-95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change -0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (-0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change -0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. INTERPRETATION Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. FUNDING Intercept Pharmaceuticals.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(19)30094-9

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 24 references

Cited by

Sorted by citations

Items 101–179 of 179

Related

See all

Metadata

Authors
Trauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., MacConell, L., & Shapiro, D.
Affiliations
  • Medical University of Vienna (AT)
  • KU Leuven (BE)
  • Bon Secours Liver Institute of Hampton Roads (US)
  • Radboud University Medical Center (NL)
  • University of California, Davis (US)
  • National Institute for Health and Care Research (GB)
  • Intercept Pharmaceuticals (United States) (US)
Corresponding author
Trauner, Michael
ORCID
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2019-06
Volume
4
Issue
6
Pages
445-453
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
DOI
10.1016/s2468-1253(19)30094-9
OpenAlex
W2922727372
Semantic Scholar
0b165ee31de96a2d016dc69d19703615a5965f51
Cited by
180
References
24
Citations by year
2026: 10 · 2025: 29 · 2024: 23 · 2023: 21 · 2022: 37 · 2021: 27 · 2020: 23 · 2019: 10
FWCI
15.46
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
Intercept Pharmaceuticals
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
obeticholic acid, primary biliary cirrhosis, long-term efficacy, drug safety, alkaline phosphatase, total bilirubin, direct bilirubin, cholestasis, liver injury, open-label extension, POISE trial, fumarate esters
MeSH terms
Alkaline Phosphatase, Bilirubin, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Dose-Response Relationship, Drug, Double-Blind Method, Fatigue, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Pruritus, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review